Getting Help With Non-Hemolytic Hyperbilirubinemia.
Hyperbilirubinemia remains a challenge for all who care for newborns. Despite the wonders of transcutaneous bilirubin (TcB) measures, when the TcB is high (and we can debate exactly which number is the trigger) a blood level is likely appropriate.2,3 ...
AAP News - Wed, 11 Nov 2015 08:30

Increased asymmetric dimethylarginine levels in severe transient tachypnea of ...
35 weeks GA with indirect hyperbilirubinemia, from whom blood was drawn for follow-up of bilirubin levels, were enrolled as controls. GA was calculated according to the last maternal menstrual period, early pregnancy ultrasound examination findings or ...
Nature.com - Thu, 11 Feb 2016 05:52



Neonatal Hyperbilirubinemia: Study Identifies Risk Profile
A set of maternal and obstetric risk factors readily available at birth predicts a greater than 100-fold variation in the incidence of nonhemolytic neonatal hyperbilirubinemia, according to a large population-based study published online November 9 in ...
Medscape - Mon, 09 Nov 2015 03:32



Clinical Review: Regorafenib in Refractory mCRC
The most frequent drug-related grade ≥3 AEs were HFSR (16%), hypertension (11%), hyperbilirubinemia, hypophosphatemia, and alanine aminotransferase increase (7%, each). “The studies showed that regorafenib improved overall survival in both Asian ...
Targeted Oncology - Wed, 10 Feb 2016 23:07

Dad Shares Photo of Baby's First Bath But It's Not Her Look That Causes ...
According to the Children's Hospital of the King's Daughters website, hyperbilirubinemia is neonatal jaundice. This can occur in up to 60% of newborns. It can be detected by the “yellow coloring of the skin and whites of the eyes” and is commonly seen ...
IJ Review - Fri, 22 Jan 2016 09:03



Low-cost filtered-sunlight therapy noninferior to conventional phototherapy in ...
Study Rundown: Severe neonatal hyperbilirubinemia, often leading to kernicterus and devastating neurologic outcomes, affects almost half a million infants annually. It disproportionately affects those in sub-Saharan Africa. Standard treatment of this ...
2 Minute Medicine - Mon, 28 Sep 2015 03:30

Exelixis Announces European Medicines Agency Acceptance of Marketing ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients ...
Business Wire (press release) - Thu, 28 Jan 2016 13:00

Baxalta Granted EU Marketing Authorization for ONCASPAR (pegaspargase) as a ...
The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) toxicity, thrombosis, coagulopathy, hyperbilirubinemia and elevated transaminases.
Business Wire (press release) - Tue, 19 Jan 2016 03:37


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014